Monthly Archives: July 2008
Alzheimer’s Wonder Drug?
The BBC reported yesterday that a new drug treatment is being trialled through research at Aberdeen University that seems to be having a significant impact on the root causes of Alzheimer’s.
The link between clumps or “tangles” of protein inside nerve cells in the brain and Alzheimer’s disease was first made over 100 years ago.
Later shown to be made up of a protein called Tau, the tangles build up inside cells involved in memory, destroying them in the process.
Rember, or methylthioninium chloride, is the first treatment specifically designed to target the Tau tangles.
Other treatments for Alzheimer’s tend to focus on combating a waste protein in the brain, beta-amyloid, which is known to form hard plaques. The latest work suggests targeting Tau may produce better results.
Although there have been other ‘wonder’ medicines in the past, this does seem to be heralded as a new development as the trials move into the next stage of trials with work also being done to look at the effects on prevention as well as a slowing of progression of Alzheimer’s.
The BBC has some stories from people who are on the trial where they explain the effects that this medication has had on them or their family members.
One of the most interesting aspects of the trial is that it is being funded by a pharmaceutical company – which the Alzheimer’s Research Trust picks up on with the Chief Executive, Rebecca Wood, stating that
“It is telling that this large trial was paid for by a pharmaceutical company. Public funding for dementia research is woefully inadequate. Cancer researchers receive ten times as much public funding as dementia scientists in the UK, yet dementia care costs are greater than those for cancer. We urgently need an increase in research funding if we are to offer hope to the 700,000 people in the UK who live with Alzheimer’s or other dementias.”
Of course, everyone is pulling on the same purse-strings so it’s hard to say one type of medical research should take precedence over another – and it’s hard not to make comparisons about availability of research money in one area as opposed to another – but it isn’t necessarily a situation of one or the other.
Pharmaceutical companies have obvious vested interests in funding research trials and while the best case would be for the research to be independent – at least the interests are openly stated. I for one, wouldn’t be too proud to use medication necessary as long as the research had integrity.
All good signs and as The Times mentions in its Comment piece
It may be some time before we can say that dementia is a controllable disease, but 100 years after Alzheimer’s was identified, that no longer seems to be an unreasonable objective.
Reasons to be cheerful – perhaps.
New Models of Dementia Care
The Daily Telegraph published the first in a two-part interview with Oliver James today – a clinical psychologist who, with his mother-in-law, Penny Garner, have developed a system of working with people who have dementia which they call:
SPECAL (Specialised Early Care for Alzheimer’s).
As the article describes, this is a model which works on triggers that are appropriate for the individual – Garner uses some examples in relation to her mother, Dorothy, who had dementia
“If while getting ready for bed, I noticed she had lost track of whether she was buttoning up the cardigan ready to go out or taking it off to go to bed, I would fiddle with my buttons alongside her and say ‘Oh good! No more travelling for us today! Glad we’ve got a bed for the night!’ I found that this simple cue was all she needed. Without it, she was inclined to get half-way through undressing and then start getting dressed again.”
The key themes of the model seem to be that:
SPECAL also teaches carers to avoid asking questions, because that means the person with dementia has to search their recent memories – and that can distress them. Carers are taught to supply reassuring information if the person with dementia asks questions. What the carer says is less important than the feelings their remark generates. The third rule is never to contradict, because that will also cause upset.
As a model, it would seem to concur with the recent evidence presented by the BBC following research carried out in Aberdeen, Abertay and St Andrews’ Universities that people with dementia may remember more than it seems and that questioning can be distressing although more facts can be recalled by patients depending on the ways that questions were asked.
With Professor Trevor Harley at Dundee University, being quoted by the BBC as having said
“we found that if you probe the patient in the right way with appropriate questions that support them to search their stored knowledge, they can often generate more detailed information.
“That is, the knowledge isn’t always lost at all. Of course eventually the information might be completely lost, but this might happen much later than people have previously thought.”
As mentioned many times before, a lot of the work I do is with people who have diagnoses of dementia. This research, these writings, all seem to point to the need to be clear and not make assumptions about what a person can or cannot understand. It is important too, that we, as professionals, term phrases, questions and discussions in ways that can best be understood.
I’m curious enough about the SPECAL training in particular to investigate further. One of the practice issues we discuss at work from time to time is the need for honesty and how important it is, or not, to validate what is being said by a patient even if it is not based in the present reality.
I honestly think the path of causing the least upset is instinctively the path that would create the most positive interactions – but its good to see it laid out in research!


